Year : 2011 | Volume
: 53 | Issue : 3 | Page : 239--243
Development of a murine animal model of depression for repeated dosing with human interferon alpha
Nagesh Koregala Siddegowda1, N Sanjay Kumar Rao2, Chittaranjan Andrade1
1 Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India
2 The Logos Centre for Cognitive Behavioural Therapy and Mental Health Promotion, Tees Esk and Wear Valley NHS Trust, County Hospital, North Road, Durham DH1 4ST, United Kingdom
Background: Neuropsychiatric adverse effects of interferon (IFN) alpha are well known. There is little clinically relevant research on animal models of depression with recombinant human IFN alpha 2b (rhIFN-α2b).
Aim: To identify an appropriate dose and duration of administration of recombinant human interferon alpha-2b
(rhIFN-α2b) to establish a convenient and clinically relevant murine model of chronic rhIFN-α2b-induced depression using the forced swim test (FST).
Materials and Methods: Using a 4΄3 factorial design, rhIFN-α2b was administered subcutaneously to mice (n=180) in the dose range of 400, 800, and 1600 IU/g/day for 5, 10, and 15 days; saline-treated mice formed the control groups. In each group, 1 day after the last dose, the mice were assessed for immobility in the FST. In another experiment, at these same doses and time points, the effect of rhIFN-α2b on murine motility was assessed in the small open field.
Results: We found that rhIFN-α2b significantly increased immobility in the FST. The immobility was detectable by day 5 and did not increase with duration of IFN treatment. The immobility was apparent with the 400 IU/g/day dose and was not greater at higher IFN doses. At no dose or time point did rhIFN-α2b alter murine motility in the small open field.
Conclusion: We conclude that rhIFN-α2b-induced behavioral despair, represented by immobility in the FST, is not due to reduced basal motility. The FST may therefore be used as a convenient Swiss albino mouse model of chronic rhIFN-α2b-induced depression with a 400-1600 IU/g/day dose administered subcutaneously for 5-15 days. The most economical model is 400 IU/g/day administered for 5 days
Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore - 560 029, Karnataka
|How to cite this article:|
Siddegowda NK, Kumar Rao N S, Andrade C. Development of a murine animal model of depression for repeated dosing with human interferon alpha.Indian J Psychiatry 2011;53:239-243
|How to cite this URL:|
Siddegowda NK, Kumar Rao N S, Andrade C. Development of a murine animal model of depression for repeated dosing with human interferon alpha. Indian J Psychiatry [serial online] 2011 [cited 2021 Sep 27 ];53:239-243
Available from: https://www.indianjpsychiatry.org/article.asp?issn=0019-5545;year=2011;volume=53;issue=3;spage=239;epage=243;aulast=Siddegowda;type=0